Search

Author/Creator Daud, Adil

32. O85 Durable responses in anti-PD-1 refractory melanoma following intratumoral injection of a toll-like receptor 9 (TLR9) agonist, CMP-001, in combination with pembrolizumab. (15th April 2020)

Authors:
Milhem, Mohammed; Zakharia, Yousef; Davar, Diwakar; Buchbinder, Elizabeth; Medina, Theresa; Daud, Adil; Ribas, Antoni; Niu, Jiaxin; Gibney, Geoffrey; Margolin, Kim; Olszanski, Anthony; Mehmi, Interjit; Sato, Takami; Shaheen, Montaser; Morris, Aaron; Mauro, David; Campbell, Katie; Bao, Riyue; Wein...
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 8(2020)Supplement 1
Page Start:
A2
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

33. Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial. (September 2018)

Authors:
Carlino, Matteo S.; Long, Georgina V.; Schadendorf, Dirk; Robert, Caroline; Ribas, Antoni; Richtig, Erika; Nyakas, Marta; Caglevic, Christian; Tarhini, Ahmed; Blank, Christian; Hoeller, Christoph; Bar-Sela, Gil; Barrow, Catherine; Wolter, Pascal; Zhou, Honghong; Emancipator, Kenneth; Jensen, Erin...
Journal:
European journal of cancer
Issue:
Volume 101(2018)
Page Start:
236
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

34. Patterns of response in patients with advanced melanoma treated with Pembrolizumab (MK-3475) and evaluation of immune-related response criteria (irRC). (6th November 2014)

Authors:
Hodi, F Stephen; Ribas, Antoni; Daud, Adil; Hamid, Omid; Robert, Caroline; Kefford, Richard; Hwu, Wen-Jen; Gangadhar, Tara C; Joshua, Anthony M; Hersey, Peter; Weber, Jeffrey; Joseph, Richard W; Zarour, Hassane; Dronca, Roxana; Gammage, Linda; Hille, Darcy; Xue, Dahai; Kang, S Peter; Chun, Patric...
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 2(2014)Supplement 3
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

36. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Issue 8 (August 2015)

Authors:
Ribas, Antoni; Puzanov, Igor; Dummer, Reinhard; Schadendorf, Dirk; Hamid, Omid; Robert, Caroline; Hodi, F Stephen; Schachter, Jacob; Pavlick, Anna C; Lewis, Karl D; Cranmer, Lee D; Blank, Christian U; O'Day, Steven J; Ascierto, Paolo A; Salama, April K S; Margolin, Kim A; Loquai, Carmen; Eigentle...
Journal:
Lancet oncology
Issue:
Volume 16:Issue 8(2015:Aug.)
Page Start:
908
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

37. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Issue 8 (August 2015)

Authors:
Ribas, Antoni; Puzanov, Igor; Dummer, Reinhard; Schadendorf, Dirk; Hamid, Omid; Robert, Caroline; Hodi, F Stephen; Schachter, Jacob; Pavlick, Anna C; Lewis, Karl D; Cranmer, Lee D; Blank, Christian U; O'Day, Steven J; Ascierto, Paolo A; Salama, April K S; Margolin, Kim A; Loquai, Carmen; Eigentle...
Journal:
Lancet oncology
Issue:
Volume 16:Issue 8(2015:Aug.)
Page Start:
908
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

38. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Issue 10105 (21st October 2017)

Authors:
Schachter, Jacob; Ribas, Antoni; Long, Georgina V; Arance, Ana; Grob, Jean-Jacques; Mortier, Laurent; Daud, Adil; Carlino, Matteo S; McNeil, Catriona; Lotem, Michal; Larkin, James; Lorigan, Paul; Neyns, Bart; Blank, Christian; Petrella, Teresa M; Hamid, Omid; Zhou, Honghong; Ebbinghaus, Scot; Ibr...
Journal:
Lancet
Issue:
Volume 390:Issue 10105(2017)
Page Start:
1853
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

39. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Issue 9 (September 2019)

Authors:
Robert, Caroline; Ribas, Antoni; Schachter, Jacob; Arance, Ana; Grob, Jean-Jacques; Mortier, Laurent; Daud, Adil; Carlino, Matteo S; McNeil, Catriona M; Lotem, Michal; Larkin, James M G; Lorigan, Paul; Neyns, Bart; Blank, Christian U; Petrella, Teresa M; Hamid, Omid; Su, Shu-Chih; Krepler, Clemen...
Journal:
Lancet oncology
Issue:
Volume 20:Issue 9(2019)
Page Start:
1239
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗